NCT04079296View on ClinicalTrials.gov

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome

Interventions

BIOLOGICAL

ASP7517

Intravenous (IV)

Trial Locations (16)

10016

NYU Langone Health, New York

33028

Memorial Healthcare System-West, Pembroke Pines

91010

City of Hope, Duarte

Unknown

Site JP81005, Nagoya

Site JP81016, Matsuyama

Site JP81009, Yoshida-gun

Site JP81004, Maebashi

Site JP81007, Kobe

Site JP81013, Isehara

Site JP81017, Sendai

Site JP81001, Shinagawa

Site JP81002, Fukuoka

Site JP81010, Gifu

Site JP81008, Okayama

Site JP81011, Osaka

Site JP81012, Osaka

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04079296 - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter